Target Name: CALCA
NCBI ID: G796
Review Report on CALCA Target / Biomarker Content of Review Report on CALCA Target / Biomarker
CALCA
Other Name(s): calcitonin 1 | Calcitonin related polypeptide alpha, transcript variant 3 | Katacalcin | Calcitonin related polypeptide alpha, transcript variant 2 | Calcitonin 1 | CGRP-I | Procalcitonin | PCT | CALCA variant 2 | Alpha-type CGRP | Calcitonin gene-related peptide 1 (isoform alpha-CGRP) | Calcitonin gene-related peptide 1 | katacalcin | Calcitonin related polypeptide alpha, transcript variant 1 | CCP | CALC_HUMAN | Calcitonin carboxyl-terminal peptide | CGRP1 | PCT_(HUMAN) | calcitonin/calcitonin-related polypeptide, alpha | CALC1 | alpha-type CGRP | CALCA variant 3 | calcitonin gene-related peptide I | CGRP | Calcitonin | CGRP-alpha | CALCA variant 1 | Calcitonin gene-related peptide I | CALCA_HUMAN | CT | KC | PDN-21 | Calcitonin/calcitonin-related polypeptide, alpha | Calcitonin Gene-Related Peptide 1 | calcitonin related polypeptide alpha

Unlocking the Potential of CALCA as a Drug Target and Biomarker

Introduction

CALCA, or calcitonin-related peptide, is a 13-peptide hormone that plays a critical role in regulating various physiological processes in the body. It is synthesized by the parotid gland and has been shown to participate in various physiological functions, including regulation of bone growth and development, immune function, and metabolism. Despite its importance,Calca is not yet widely recognized as a drug target or biomarker. In this article, we will explore the potential of CALCA as a drug target and biomarker, and discuss the current research on its potential clinical applications.

Drug Target

Calca has been identified as a potential drug target due to its unique biology and various biological pathways involved in its regulation. One of the key factors that make Calca an attractive drug target is its extracellular domain, which is composed of a series ofcalcitonin-like repeats . These repeats have been shown to interact with various signaling, including the TGF-β pathway. This pathway is involved in regulating cellular processes that are crucial for tissue growth, differentiation, and repair, and is a key factor in the development and maintenance of various diseases, including cancer.

The TGF-β pathway is known for its role in promoting uncontrolled cell growth, which is a major contributor to the development of many diseases, including cancer. By targeting the TGF-β pathway, Calca has the potential to inhibit uncontrolled cell growth and promote cell death, which could be a valuable therapeutic approach for the treatment of various diseases.

Biomarker

Calca has also been identified as a potential biomarker due to its unique biology and various biological pathways involved in its regulation. One of the key factors that make Calca an attractive biomarker is its ability to be recombinantly expressed in various cell types, including cancer cells. This allows researchers to use Calca as a tool for the study of various biological processes, including cancer cell biology, stem cell biology, and tissue engineering.

In addition, Calca has been shown to have various biological activities that are relevant to its potential use as a biomarker. For example, Calca has been shown to regulate the activity of various signaling pathways, including the TGF-β pathway. This pathway is involved in regulating cellular processes that are crucial for tissue growth, differentiation, and repair, and is a key factor in the development and maintenance of various diseases, including cancer.

Calca has also been shown to participate in various signaling pathways that are involved in the regulation of inflammation and immune function. This suggests that Calca may have potential as a biomarker for the study of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

Potential Clinical Applications

The potential clinical applications of Calca as a drug target and biomarker are vast and varied. One of the key potential applications of Calca is its use as a therapeutic agent for the treatment of various cancers, including breast, lung, and ovarian cancers. By targeting the TGF-β pathway and inhibiting uncontrolled cell growth, Calca has the potential to promote cell death and inhibit the growth of cancer cells, which could be a valuable therapeutic approach for the treatment of various cancers.

In addition to its potential use as a cancer therapeutic, Calca has also been shown to have potential as a diagnostic agent. The recombinant expression of Calca in various cell types allows researchers to use Calca as a tool for the study of various biological processes, including cancer cell biology, stem cell biology, and tissue engineering. This suggests that Calca may have potential as a diagnostic agent for the detection and diagnosis of various diseases.

Conclusion

In conclusion, Calca has the potential to be a drug target and biomarker due to its unique biology and various biological pathways involved in its regulation. The TGF-β pathway, inflammation, and immune function are some of the key biological pathways that are involved in the regulation of Calca. Its potential clinical applications are vast and varied, including the treatment of various cancers and the diagnosis of

Protein Name: Calcitonin Related Polypeptide Alpha

Functions: Calcitonin causes a rapid but short-lived drop in the level of calcium and phosphate in blood by promoting the incorporation of those ions in the bones

The "CALCA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CALCA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CALCB | Calcium channel | Calcium release-activated channel (CRAC) | Calcium-activated chloride channel regulators | Calcium-Activated K(Ca) Potassium Channel | CALCOCO1 | CALCOCO2 | CALCR | CALCRL | CALCRL-AS1 | CALD1 | CALHM1 | CALHM2 | CALHM3 | CALHM4 | CALHM5 | CALHM6 | CALM1 | CALM2 | CALM2P1 | CALM2P2 | CALM3 | CALML3 | CALML3-AS1 | CALML4 | CALML5 | CALML6 | Calmodulin | CALN1 | Calpain | Calpain-13 | Calprotectin | CALR | CALR3 | CALU | CALY | CAMK1 | CAMK1D | CAMK1G | CAMK2A | CAMK2B | CAMK2D | CAMK2G | CAMK2N1 | CAMK2N2 | CAMK4 | CAMKK1 | CAMKK2 | CAMKMT | CAMKV | CAMLG | CAMP | cAMP Phosphodiesterase | cAMP Responsive Element Binding Protein (CREB) | cAMP-Dependent protein kinase (PKA) | CAMSAP1 | CAMSAP2 | CAMSAP3 | CAMTA1 | CAMTA2 | CAND1 | CAND1.11 | CAND2 | Cannabinoid receptor | CANT1 | CANX | Cap-binding complex | CAP1 | CAP2 | CAPG | CAPN1 | CAPN10 | CAPN10-DT | CAPN11 | CAPN12 | CAPN13 | CAPN14 | CAPN15 | CAPN2 | CAPN3 | CAPN5 | CAPN6 | CAPN7 | CAPN8 | CAPN9 | CAPNS1 | CAPNS2 | CAPRIN1 | CAPRIN2 | CAPS | CAPS2 | CAPSL | CAPZA1 | CAPZA2 | CAPZA3 | CAPZB | Carbonic Anhydrase | Carbonic Anhydrase V | Carboxylesterase | Carboxypeptidase A